Funding for this research was provided by:
Universitätsklinik München
Article History
Received: 12 March 2023
Revised: 12 April 2023
Accepted: 13 April 2023
First Online: 27 April 2023
Declarations
:
: M. Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker’s honoraria from Abbott, Auris Medical, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, J&J, MSD, NeuroUpdate, Otometrics, Pierre-Fabre, TEVA, UCB, and Viatris. He receives support for clinical studies from Decibel, U.S.A., Cure within Reach, U.S.A. and Heel, Germany. He distributes “M-glasses” and “Positional vertigo App”. He acts as a consultant for Abbott, AurisMedical, Heel, IntraBio and Sensorion. He is a sharholder, investor and chief medical officer of IntraBio. S. Bardins is a shareholder of EyeSeeTec GmbH, manufacturer of the eye-tracking equipment used in the study.